TriPath submits PMA (premarket approval) supplement for screener:
This article was originally published in Clinica
Executive Summary
TriPath Imaging is seeking a US premarket approval(PMA) supplement for permission to screen thin-layer specimens on its fully automated primary screening system. The PMA supplement provides clinical data that demonstrates the performance of the AutoPap system as a primary screener for slides produced by the AutoCyte PREP system, an automated liquid-based, thin-layer sample preparation system. The Burlington, North Carolina-based company, has been created through the merger of NeoPath and AutoCyte (see Clinica No 879, p 17). Both systems are already approved for sale in the US.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.